Wegovy® supply update

Investor conference call

20 December 2021
Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company's statutory Annual Report 2020 and Form 20-F, which was filed with the SEC in February 2021 in continuation of the publication of the Annual Report 2020, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘project’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

- Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as co-operation in relation thereto,
- Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,
- Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
- Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, failure to maintain a culture of compliance, and epidemics pandemics or other public health crises.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in this presentation, reference is made to the overview of risk factors in ‘Risk management’ of the Annual Report 2020.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise.

Important drug information
- Victoza® and Ozempic® are approved for the management of type 2 diabetes only
- Saxenda® is approved in the USA and the EU for the treatment of obesity only and Wegovy® is approved in the USA
Executive summary - Wegovy® supply update

Wegovy® addresses a huge unmet need
• More than 650 million living with obesity globally
• Wegovy® demonstrated a weight loss of 17-18%\(^1\)
• Overwhelming demand with Wegovy® total scripts at Saxenda® level just 5 weeks into the launch

Novo Nordisk was on-track to meet demand in the US in early 2022
• Revised capacity plans for Wegovy® following overwhelming initial demand
• Significant progress made on ramping up supply across all doses to meet demand in early 2022
• Prepared sales force and promotional efforts to support Wegovy®

cGMP compliance issues delays stabilisation of Wegovy® supply
• Novo Nordisk notified by CMO Friday 17 December 2021 on supply consequences of cGMP issues
• Large contract manufacturer temporarily stops deliveries and manufacturing due to cGMP issues

Expectation of meeting demand in the US in second half of 2022
• Plan in place to address the new supply challenges
• Few new patients are expected to initiate treatment in first half of 2022 – focus on patients on treatment today
• Supply stabilisation delayed until second half of 2022 based on current assessment of issues

\(^1\) Based on the trial product estimand in STEP clinical trials in people with obesity without diabetes; cGMP: current Good Manufacturing Practice
Significant ramp-up of production capacity has taken place but ability to meet demand delayed due to cGMP issues at CMO

**Wegovy® simplified manufacturing process**

**Update on supply chain for Wegovy®**

- Capacity expansion plans were well on track
- Large global contract manufacturing organisation received a 483 letter by the US FDA
- The letter addresses cGMP issues at production site for Wegovy® syringes
- Findings are not related directly to production of Wegovy®
- Deliveries and manufacturing from the site have temporarily stopped
- Product recall is currently not expected

API: Active Pharmaceutical Ingredient, CMO: Contract Manufacturing Organisation, cGMP: current Good Manufacturing Practice, FDA: Food and Drug Administration
Plan in place to address cGMP issues and increase Wegovy® supply

- Close collaboration between CMO and Novo Nordisk to address the cGMP issues as fast as possible
- Utilisation of internal Novo Nordisk filling capacity
- Strategy: Ensuring multiple production sites
- Plan for launching Wegovy® outside of the US in existing Novo Nordisk platform

CMO: Contract Manufacturing Organisation, cGMP: current Good Manufacturing Practice
Confident in potential of Wegovy®

Implications of supply chain challenges for Wegovy®

- Novo Nordisk expects to be able to meet demand in the US in the second half of 2022, assuming successful mitigation of CMO cGMP issues.
- The key priority is for patients who have already initiated treatment of Wegovy® to be able to stay on treatment.
- Supply capacity in the first half of 2022 is expected to be at around 60-90% of current TRx level.
- Confidence in Wegovy® and commitment to patients living with obesity remain unchanged.

AOM: Anti-obesity medications (includes Wegovy®, Saxenda®, Qsymia and Contrave); TRx: Total prescriptions; cGMP: current Good Manufacturing Practice
Source: IQVIA NPA – TRx data weekly (week ending 3 December 2021)
Investor contact information

Share information
Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen under the symbol ‘NOVO B’. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.

For further company information, visit Novo Nordisk on: www.novonordisk.com

Upcoming events

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>02 February 2022</td>
<td>Financial statement for 2021</td>
</tr>
<tr>
<td>03 March 2022</td>
<td>Capital Markets Day in Copenhagen, Denmark</td>
</tr>
<tr>
<td>24 March 2022</td>
<td>Annual General Meeting</td>
</tr>
<tr>
<td>04 May 2022</td>
<td>Financial statement for the first three months of 2022</td>
</tr>
<tr>
<td>04 August 2022</td>
<td>Financial statement for the first six months of 2022</td>
</tr>
<tr>
<td>02 November 2022</td>
<td>Financial statement for the first nine months of 2022</td>
</tr>
</tbody>
</table>

Investor Relations contacts

Novo Nordisk A/S
Investor Relations
Novo Allé
DK-2880 Bagsværd

<table>
<thead>
<tr>
<th>Name</th>
<th>Phone Number</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Muusmann Bohsen</td>
<td>+45 3075 2175</td>
<td><a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a></td>
</tr>
<tr>
<td>Ann Søndermølle Rendbæk</td>
<td>+45 3075 2253</td>
<td><a href="mailto:arnd@novonordisk.com">arnd@novonordisk.com</a></td>
</tr>
<tr>
<td>David Heiberg Landsted</td>
<td>+45 3077 6915</td>
<td><a href="mailto:dhel@novonordisk.com">dhel@novonordisk.com</a></td>
</tr>
<tr>
<td>Mark Joseph Root (USA)</td>
<td>+1 848 213 3219</td>
<td><a href="mailto:mjhr@novonordisk.com">mjhr@novonordisk.com</a></td>
</tr>
</tbody>
</table>